Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | SRC | P12931 | 2/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1206380 | 1.00 | LMNA (0.52) | LMNAMAPK1KDM4EALDH1A1HPGD | |
| SCHEMBL6739918 | 0.77 | HDAC1 (0.45) | LMNAMAPK1KDM4EALDH1A1GAA | |
| SCHEMBL7384844 | 0.77 | HDAC1 (0.45) | LMNAMAPK1KDM4EALDH1A1GAA | |
| SCHEMBL6739916 | 0.77 | HDAC1 (0.45) | LMNAMAPK1KDM4EALDH1A1GAA | |
| SCHEMBL10329425 | 0.76 | LMNA (0.50) | LMNAMAPK1KDM4EALDH1A1HPGD | |
| SCHEMBL29988941 | 0.76 | LMNA (0.50) | LMNAMAPK1KDM4EALDH1A1HPGD | |
| SCHEMBL15005865 | 0.75 | ALDH1A1 (0.48) | ALDH1A1GAAMTORSRCALOX5 | |
| Mandelic Acid SCHEMBL1131369 | 0.74 | LMNA (0.72) | LMNAMAPK1KDM4EALDH1A1HPGD | |
| SCHEMBL5847528 | 0.74 | HTR2A (0.52) | LMNAMAPK1KDM4EALDH1A1HPGD | |
| SCHEMBL29103977 | 0.73 | SMN1; SMN2 (0.58) | LMNAMAPK1KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1979356-B1 | CARBONYLAMINO PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | PFIZER PROD INC (US) | 2013-09-18 | — | — | EP | disclosed |
| US-7884117-B2 | Protein kinase inhibitors such as (S)-2-(methylamino)-1-phenylethyl 3-(4-fluorobenzamido)-6,6-dimethylpyrrolo[3,4-c]pyrazole-5(1H,4H,6H)-carboxylate, used for the treatment of abnormal cell growth in mammals; antiproliferative agents | PFIZER INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-20090318440-A1 | CARBONYLAMINO PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | PFIZER INC. | 2009-12-24 | — | — | US | disclosed |
| EP-1979356-A2 | CARBONYLAMINO PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | Pfizer Products Inc. (US) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007072153-A2 | CARBONYLAMINO PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318440-A1 | CARBONYLAMINO PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | PAK4, PAK5, PAK3 | LMNA 3611/4885MAPK1 78/4885KDM4E 1361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.